The effects in viability of HeLa and SiHa monolayers treated or untreated with 100, 200 and 400 μM of I2 for 24 h and HeLa cervospheres treated or untreated with 200 μM of I2 for 24 h, were analyzed using the OZBlue Cell Viability Kit (OZ Biosciences, San Diego, USA) following the supplier’s instructions.
Ozblue cell viability kit
Manufactured by Ozyme
Sourced in United States, France
The OZBlue Cell Viability Kit is a laboratory tool designed for assessing cell viability. It provides a reliable method for quantifying the number of living cells in a sample.
Automatically generated - may contain errors
Lab products found in correlation
Chs 828, by Cayman Chemical (2 mentions)
L asparaginase, by Merck Group (1 mentions)
Jph203, by Merck Group (1 mentions)
Jph203, by Bio-Techne (1 mentions)
Xtt assay, by Thermo Fisher Scientific (1 mentions)
2 deoxyglucose, by Merck Group (1 mentions)
Oligomycin a, by Merck Group (1 mentions)
Methyl thiazolyl tetrazolium (mtt), by Merck Group (1 mentions)
Mf14000, by Ozyme (1 mentions)
Rosiglitazone, by Merck Group (1 mentions)
Fk866, by Santa Cruz Biotechnology (1 mentions)
Antimycin a, by Merck Group (1 mentions)
Cisplatin, by Merck Group (1 mentions)
Verapamil, by Merck Group (1 mentions)
Uk5099, by Merck Group (1 mentions)
Olaparib, by MedChemExpress (1 mentions)
5 protocols using ozblue cell viability kit
1
I2-Induced Viability Effects in HeLa and SiHa Cells
2
Evaluation of Anticancer Drug Synergy
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
CCRF-CEM and MDA MB231 cells were treated with FK866, CHS-828 (200484-11-3, Cayman Chemical), oligomycin A (75351, Sigma), 2-deoxyglucose (D8375, Sigma), GSK2837808A (GSK) (5189, Tocris), JPH203 (a selective L-type amino acid transporter), and l -asparaginase (11185, Sigma) for 48 h. JPH203 was kindly obtained from Dr. Peyron [30 (link)]. In vitro drug sensitivity was assessed by the colorimetric methyl-thiazolyltetrazolium (MTT) assay (sigma), XTT proliferation kit (sigma), and OZBlue Cell Viability kit (OZbiosciences). Combination treatment of FK866 with JPH203 was performed and 48 h after combination treatment, Cell viability was determined using XTT assay (Invitrogen) and DAPI staining. Percentage of cell death was subjected for drug combination analysis as described by combination index (CI). CI was analyzed using CompuSyn software V1.0 by the method of Chou and Talalay [31 (link)]. CI < 1 indicates drug synergistic effect, CI > 1 indicates drug antagonistic effect, and CI = 1 indicates drug additive effect.
3
Cell Viability Assays for Drug Sensitivity
Check if the same lab product or an alternative is used in the 5 most similar protocols
In vitro drug sensitivity was assessed in HEK293T cells by the fluorescent and colorimetric OZBlue CellViability kit (OZbiosciences). HEK293T cells were plated at 1.2 × 104 in 96‐well plates and treated for 24 h with different concentrations of compounds (and DMSO as vehicle), and at 2.5 × 103 for siRNA experiments (72 h). Eight microliters of OZBlue was added to the media and incubated for 3 h. Fluorescence measuring (560 nm Ex/590 nm Em) was determined using a plate reading at the following time‐point 1, 2 and 3 h.
The 3‐(4,5‐dimethyl‐2‐thiazolyl)‐2,5 diphenyl‐2H‐tetrazolium bromide (MTT; Sigma‐Aldrich)‐based cell proliferation assay (MTT assay) was carried out on NSC34 cells 24 h with selected compounds and performed in 24‐well plates at 4 × 104 cells/well (6 wells for each condition to be tested; n = 6). MTT solution was prepared at 1.5 mg/ml in DMEM without phenol red and was filtered through a 0.2‐mm filter. Then, the culture medium was removed from the plate and 300 µl of MTT solution was added into each well. Cells were incubated for 30 min at 37°C with 5% CO2, 95% air and complete humidity, then 500 μl of 2‐propanol was added into each well and the precipitates were suspended. The optical density (OD) of the wells was determined using a plate reader at a wavelength of 550 nm.
+ Expand
In vitro drug sensitivity was assessed in HEK293T cells by the fluorescent and colorimetric OZBlue CellViability kit (OZbiosciences). HEK293T cells were plated at 1.2 × 104 in 96‐well plates and treated for 24 h with different concentrations of compounds (and DMSO as vehicle), and at 2.5 × 103 for siRNA experiments (72 h). Eight microliters of OZBlue was added to the media and incubated for 3 h. Fluorescence measuring (560 nm Ex/590 nm Em) was determined using a plate reading at the following time‐point 1, 2 and 3 h.
The 3‐(4,5‐dimethyl‐2‐thiazolyl)‐2,5 diphenyl‐2H‐tetrazolium bromide (MTT; Sigma‐Aldrich)‐based cell proliferation assay (MTT assay) was carried out on NSC34 cells 24 h with selected compounds and performed in 24‐well plates at 4 × 104 cells/well (6 wells for each condition to be tested; n = 6). MTT solution was prepared at 1.5 mg/ml in DMEM without phenol red and was filtered through a 0.2‐mm filter. Then, the culture medium was removed from the plate and 300 µl of MTT solution was added into each well. Cells were incubated for 30 min at 37°C with 5% CO2, 95% air and complete humidity, then 500 μl of 2‐propanol was added into each well and the precipitates were suspended. The optical density (OD) of the wells was determined using a plate reader at a wavelength of 550 nm.
4
MNP Cytotoxicity Evaluation on 661W and RPE1 Cells
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The cell viability was studied using an OZ Blue Cell Viability kit (OZ Biosciences, France) following the manufacturer’s indication, with slight modifications. Briefly, one day prior to the assay, 661 W and RPE1 cells were trypsinized and seeded at 20,000 cells per well in a 96-well plate. The next day, both cell lines were exposed to increasing concentrations of the two MNPs (loaded and unloaded with drugs) and the MNPs mixture formulation in 5% glucose. The vehicle alone (5% glucose) was used as a control. After the addition of the MNPs into the wells, the plate was placed on a magnetic plate (OZ Biosciences, #MF14000) for 15 min at 37 °C to perform the magnetic targeting, as in Magnetofection™, as described elsewhere [27 (link)]. Then, the magnetic field was removed and the cells were incubated for 24 h. Thereafter, the cell viability was monitored using an OZ Blue Cell Viability kit through fluorescence measurement (560 nmEx/590 nmEm) with a cytofluor multi-well plate reader series 4000 (Perseptive Biosystems, Framingham, MA, USA). The experiments were repeated in triplicates. The results were expressed as the percentage compared to the control condition (cells treated only with vehicle, glucose 5%).
5
Cell Viability Assay for Drug Screening
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
PAR and RES cells were treated with FK866 (sc-205325, Santa Cruz Biotechnology), CHS-828 (200484-11-3, Cayman Chemical), verapamil (V4629, Sigma), antimycin A (A8674, Sigma), 5-FU (F6627, Sigma), cisplatin (PHR1624, Sigma), olaparib (HY-10162, MedChemExpress), UK5099 (5048170002, Sigma) and rosiglitazone (R2408, Sigma) for 48 h. In vitro drug sensitivity was assessed by OzBlue Cell Viability kit (OzBiosciences) after 2 h of incubation, according to the manufacturer instructions.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!